849671-56-3

Usage

Uses

Used in Organic Synthesis:
SPIRO[2.5]OCT-6-YL-METHANOL is used as a building block for the preparation of various biologically active molecules, contributing to the development of new organic compounds with potential applications in different industries.
Used in Medicinal Chemistry:
In the pharmaceutical industry, SPIRO[2.5]OCT-6-YL-METHANOL is used as a key intermediate in the synthesis of pharmaceuticals, aiding in the creation of new drugs with improved therapeutic properties.
Used in Agrochemicals:
SPIRO[2.5]OCT-6-YL-METHANOL is used as a component in the synthesis of agrochemicals, such as pesticides and herbicides, to enhance their effectiveness in agricultural applications.
Used in the Development of Novel Materials:
SPIRO[2.5]OCT-6-YL-METHANOL is used as a precursor in the development of new materials, leveraging its interesting physicochemical properties to create innovative products with unique characteristics.
Used in Catalyst Development:
In the field of catalysis, SPIRO[2.5]OCT-6-YL-METHANOL is used in the design and synthesis of new catalysts, potentially improving the efficiency of chemical reactions and processes in various industries.

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 145576-28-9 ethyl 4-methylidenecyclohexanecarboxylate 
• 75-11-6 diiodomethane 
• 1004-24-6 4-methylene-1-cyclohexanemethanol 

Downstream Products

• 1180557-35-0 C₁₆H₂₂O₃S 

Relevant academic research and scientific papers

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.

COMPOSITIONS AND METHODS FOR MODULATING FXR

The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

We describe here orally active and brain-penetrant cathepsin S selective inhibitors, which are virtually devoid of hERG K+ channel affinity, yet exhibit nanomolar potency against cathepsin S and over 100-fold selectivity to cathepsin L. The new

4-Amino-2-cyanopyrimidines: Novel scaffold for nonpeptidic cathepsin S inhibitors

We describe here a novel 4-amino-2-cyanopyrimidine scaffold for nonpeptidomimetic cathepsin S selective inhibitors. Some of the synthesized compounds have sub-nanomolar potency and high selectivity toward cathepsin S along with promising pharmacokinetic a

INHIBITORS OF CATHEPSIN S

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.